Related Experiment Videos
[Early diagnosis of glaucoma with pattern-ERG]
P Uclés1, C Almárcegui, F J Fernández
1Service de Neurophysiologie Clinique, Hospital Miguel Servet, Zaragoza, Espagne.
Journal Francais D'Ophtalmologie
|January 1, 1997
Summary
The N95 amplitude in pattern-electroretinogram (PERG) is the most sensitive indicator for early glaucoma detection. Gold foil electrodes offer superior sensitivity compared to wire electrodes for diagnosing retinal ganglion cell impairment.
Area of Science:
- Ophthalmology
- Neuroscience
- Medical Diagnostics
Background:
- Glaucoma diagnosis relies on electrophysiological techniques like pattern-electroretinogram (PERG) and visual evoked potentials (VEP).
- PERG has emerged as a key functional indicator for assessing retinal ganglion cells over the past decade.
Purpose of the Study:
- To compare the diagnostic sensitivity of PERG and VEP in detecting early glaucoma.
- To evaluate the effectiveness of gold foil electrodes versus wire electrodes in PERG recordings for glaucoma detection.
Main Methods:
- Investigated 171 eyes from 89 subjects, including those with ocular hypertension (OHT), simple chronic glaucoma (SCG), and healthy controls.
- Utilized both PERG with gold foil electrodes and VEP, analyzing components like N95 amplitude and P100 latency.
Main Results:
- Significant differences in N95 amplitude were observed in SCG (p < 0.01) and OHT (p < 0.05) groups.
- Fast Fourier Transform (FFT) analysis of PERG showed a dominant frequency difference between OHT and control groups (3.3 Hz vs. 9.9 Hz).
- VEP analysis revealed a significant delay in P100 latency exclusively in the SCG group.
Conclusions:
- N95 amplitude in PERG is identified as the most sensitive electrophysiologic parameter for early glaucoma detection.
- Gold foil electrodes provide higher amplitude and reduced variability for the N95 component compared to wire electrodes.
- This suggests gold foil electrode PERG is optimal for detecting early retinal ganglion cell impairment in ocular hypertension and glaucoma patients.